No headlines found.
electroCore's Truvaga Plus Wins Woman's World Magazine 50 over 50 Award
Globe Newswire (Wed, 20-Nov 8:00 AM ET)
electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis
Globe Newswire (Tue, 19-Nov 8:00 AM ET)
Globe Newswire (Thu, 14-Nov 8:00 AM ET)
electroCore Announces Third Quarter 2024 Financial Results
Globe Newswire (Wed, 13-Nov 4:01 PM ET)
ElectroCore's Truvaga Plus Wins Men's Health Magazine Tech Award
Globe Newswire (Tue, 12-Nov 4:01 PM ET)
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 8-Nov 4:01 PM ET)
Globe Newswire (Wed, 23-Oct 8:00 AM ET)
electroCore to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 26-Sep 8:00 AM ET)
electroCore Engages FNK IR to Execute Expanded Investor Relations Program
Globe Newswire (Tue, 24-Sep 8:00 AM ET)
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Electrocore trades on the NASDAQ stock market under the symbol ECOR.
As of December 16, 2024, ECOR stock price climbed to $13.73 with 17,023 million shares trading.
ECOR has a beta of 1.17, meaning it tends to be more sensitive to market movements. ECOR has a correlation of 0.07 to the broad based SPY ETF.
ECOR has a market cap of $89.99 million. This is considered a Micro Cap stock.
Last quarter Electrocore reported $7 million in Revenue and -$.31 earnings per share. This beat revenue expectation by $64,000 and exceeded earnings estimates by $.02.
In the last 3 years, ECOR traded as high as $15.25 and as low as $2.92.
The top ETF exchange traded funds that ECOR belongs to (by Net Assets): VTI, VXF, IWC.
ECOR has outperformed the market in the last year with a price return of +157.6% while the SPY ETF gained +30.3%. ECOR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +125.1% and +12.5%, respectively, while the SPY returned +8.1% and +0.6%, respectively.
ECOR support price is $12.65 and resistance is $14.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ECOR shares will trade within this expected range on the day.